Ahmad Al‐Huniti

ORCID: 0000-0003-3476-4132
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hemophilia Treatment and Research
  • Platelet Disorders and Treatments
  • Trauma, Hemostasis, Coagulopathy, Resuscitation
  • Blood Coagulation and Thrombosis Mechanisms
  • Child Abuse and Related Trauma
  • Iron Metabolism and Disorders
  • Vascular Malformations and Hemangiomas
  • Erythropoietin and Anemia Treatment
  • Bipolar Disorder and Treatment
  • Hematopoietic Stem Cell Transplantation
  • Blood disorders and treatments
  • Acute Myeloid Leukemia Research
  • Hemoglobinopathies and Related Disorders
  • Cancer-related gene regulation
  • Blood transfusion and management
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders
  • Abdominal Trauma and Injuries
  • Vascular Tumors and Angiosarcomas
  • Trace Elements in Health
  • Restraint-Related Deaths
  • Blood donation and transfusion practices
  • Gastrointestinal Bleeding Diagnosis and Treatment
  • Central Venous Catheters and Hemodialysis
  • Vascular anomalies and interventions

Mayo Clinic
2022-2025

Mayo Clinic in Arizona
2024-2025

University of Iowa
2019-2024

WinnMed
2022

University of Toronto
2021

Hospital for Sick Children
2020-2021

SickKids Foundation
2021

University of Iowa Stead Family Children’s Hospital
2019-2020

University of Iowa Hospitals and Clinics
2018

ABSTRACT Patients with vascular anomalies (VAs) require expert multidisciplinary care. No prior studies have characterized the sociodemographic characteristics across multiple VA centers. We collected data on 5783 patients receiving care at 20 centers between July 1, 2020 through December 31, 2022. Male were underrepresented compared to state‐level census 17/20 Black and Asian 14/20 12/20 centers, respectively. The median distance hospital was 48 miles, age 12.0 years. These suggest that...

10.1002/pbc.31661 article EN Pediatric Blood & Cancer 2025-03-17

Background: The objective of this study was to describe thrombin generation in children undergoing cardiac surgery with cardiopulmonary bypass (CPB). Change the endogenous potential (ETP) across three measurements before and after CPB (after protamine at chest closure) primary outcome. Secondary analyses explored an association between transfusion requirements predictors decline. Methods: Blood samples (median age 6.3 months; 68.5% weighed <10 kg) were collected intraoperatively times:...

10.1097/aln.0000000000005502 article EN Anesthesiology 2025-04-14

Graft thrombosis is a preventable cause of early allograft loss after pediatric kidney transplant, but the role primary thromboprophylaxis uncertain. To determine effectiveness and safety in preventing graft among children (0-21 years) undergoing transplant. We performed systematic literature review MEDLINE, Embase, Cochrane Libraries from inception until September 2024. The outcome assessed by meta-analysis was thrombosis, secondary major bleeding (per International Society on Thrombosis...

10.1016/j.jtha.2025.04.032 article EN cc-by Journal of Thrombosis and Haemostasis 2025-05-01

Iron and other biologically important metals are essential to mitochondrial function but not routinely evaluated. Their equilibrium is critical the optimal performance of cells with high metabolic activity such as neurons, cardiomyocytes, skeletal myocytes. Teenagers at a risk iron deficiency even without anemia. Metal ion imbalances can cause cognitive impairments, muscle weakness, sudden cardiac death. We aim assess current prevalence among collegiate athletes in Upper Midwest.

10.1002/pbc.31437 article EN Pediatric Blood & Cancer 2024-11-11

A recent randomized trial, the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET), confirmed that exposure to recombinant FVIII (rFVIII) products doubled risk inhibitor development compared plasma-derived (pdFVIII) previously untreated (or minimally treated) patients (PUPs) with severe haemophilia A. SIPPET post hoc analyses showed early rFVIII was more immunogenic and could harm low-risk PUPs non-null mutations. Clinical implications findings for community were unclear.Study...

10.1111/hae.13806 article EN Haemophilia 2019-07-02

Background: Thrombopoietin receptor agonists are emerging as a therapeutic option for patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS). We report our experience of treating children AA/MDS romiplostim, thrombopoietin agonist. Observations: Three (AA, 2; MDS, 1) received romiplostim treatment at median dose 10 μg/kg/week (starting dose: 5 μg/kg/wk; 2.5 μg/kg/wk increment). Trilineage hematopoietic recovery occurred 13 weeks (range: to 16 wk) without adverse events....

10.1097/mph.0000000000001810 article EN Journal of Pediatric Hematology/Oncology 2020-04-24

Abstract Background Ε‐Aminocaproic acid oral solution (EACA OS) is the only commercially available antifibrinolytic for patients who cannot swallow tablets. Insurance denials and high costs remain barriers to its use. Objectives To determine safety efficacy of crushed tranexamic tablets in water (cTXAw) children with bleeding disorders. Methods We retrospectively reviewed records (<10 years) disorders received cTXAw or EACA OS from 1 December 2018, through 31 July 2022, at Mayo Clinic...

10.1111/hae.14996 article EN Haemophilia 2024-03-20

Thrombopoietin receptor agonists (TPO-RAs) induce trilineage hematopoiesis under conditions with acquired hematopoietic failure. We evaluated safety, tolerability, and preliminary efficacy of a TPO-RA, romiplostim (Nplate), or without standard-of-care immunosuppressive therapy (±IST) for children (ages < 21 y) newly diagnosed relapsed/refractory severe aplastic anemia (SAA) myelodysplastic syndrome (MDS). Data were collected from an observational study single arm interventional pilot...

10.1097/mph.0000000000002891 article EN Journal of Pediatric Hematology/Oncology 2024-05-24

The effect of factor VIII (FVIII) deficiency, a protein essential for blood coagulation, on neurocognitive outcomes in children with hemophilia A (HA) is not well characterized. To examine differences brain volume and neurocognition between severe HA healthy controls. This single-center study included 32 males aged 6-16 years, nine FVIII deficiency 23 Volumetric data from magnetic resonance imaging (MRI) testing were compared using linear models including age to evaluate the association...

10.1016/j.bvth.2024.100021 article EN cc-by-nc-nd Deleted Journal 2024-07-26

Purpose: Fibroadipose vascular anomaly (FAVA) is a complex associated with postzygotic somatic PIK3CA mutations. FAVAs can cause significant pain, swelling, and musculoskeletal dysfunction. Treatment options are limited. Sirolimus well-tolerated effective treatment for patients FAVA. We report our experience of using sirolimus to treat 11 children FAVAs. Methods: conducted retrospective review all FAVA treated in institution. Results: Fourteen (10 females) were referred therapy Eleven...

10.1097/jova.0000000000000030 article EN cc-by-nc-nd Journal of Vascular Anomalies 2021-11-24
Coming Soon ...